Review anchor
Corticotropin-releasing factor receptor 1
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
Evidence Snapshot
Corticotropin-releasing factor receptor 1
CHEMBL1800
SINGLE PROTEIN
Homo sapiens
Identity Layer
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Corticotropin-releasing factor receptor 1 as ChEMBL target CHEMBL1800, mapped to UniProt P34998. Disease framing currently uses the Open Targets-ready proxy contract.
ChEMBL target ID
CHEMBL1800
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine
As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P34998
Corticotropin-releasing factor receptor 1
UniProt accession via ChEMBL component mapping
As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy
As of 2026-09-13
www.ebi.ac.uk
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Review-ready Target Rationale
Why Corticotropin-releasing factor receptor 1 matters
Corticotropin-releasing factor receptor 1 is reviewed as Corticotropin-releasing factor receptor 1 (UniProt P34998); Corticotropin-releasing factor receptor 1 shows approved-linked disease relevance led by congenital adrenal hyperplasia. 5 more disease programs remain visible in the same review block.; 2 linked drugs keep this evidence frame grounded.; the current evidence base includes 1 approved drug, 2495 compounds, and 193 assays, with lead potency reaching pChEMBL 9.8.
Protein context
Corticotropin-releasing factor receptor 1
Corticotropin-releasing factor receptor 1 Sequence length is 415 aa.
Review this target as Corticotropin-releasing factor receptor 1, mapped to UniProt P34998. Sequence length is 415 aa.
Protein source · UniProt accession via ChEMBL component mapping
UniProt P34998
Protein
Disease context
congenital adrenal hyperplasia
Corticotropin-releasing factor receptor 1 shows approved-linked disease relevance led by congenital adrenal hyperplasia. 5 more disease programs remain visible in the same review block. 2 linked drugs keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include CRINECERFONT, VERUCERFONT.
Start review with congenital adrenal hyperplasia because it currently carries approved-linked support. Linked drugs include CRINECERFONT, VERUCERFONT. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target record
Approved-linked
2 linked drugs
Activity base
Portfolio and assay base
ChEMBL currently tracks 1 approved drug, 2495 compounds, and 193 assays for this target. The dominant activity type is KI. CHEMBL4299295 is the current potency anchor at pChEMBL 9.8.
Use CHEMBL4299295 as the tractability anchor when discussing potency (pChEMBL 9.8).
Activity source · ChEMBL 36 via Core Engine
1 approved
pChEMBL 9.8
Source Guidance
Start with the right source
Pick the first block or linked source that matches the review question in front of you.
Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution
Start with the review rationale when you need to explain why Corticotropin-releasing factor receptor 1 matters before drilling into raw source blocks.
Jump to Review RationaleNeed stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping
Go back to the target snapshot when you need the naming and mapping contract behind UniProt P34998, not just the summarized rationale.
Open Protein ContextNeed disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy
Use the target snapshot disease block when you need to see why congenital adrenal hyperplasia is currently treated as approved-linked support.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
2495
Total Compounds
193
Total Assays
1
Approved Drugs
IC50: 814.0, KI: 1642.0, EC50: 108.0, KD: 8.0
Activity Types
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL4299295
|
9.8 | Ki | — |
|
|
No preferred name
CHEMBL3775796
|
9.7 | Ki | — |
|
|
No preferred name
CHEMBL3774395
|
9.7 | Ki | — |
|
|
No preferred name
CHEMBL498311
|
9.7 | Ki | — |
|
|
No preferred name
CHEMBL4299341
|
9.7 | Ki | — |
Approved Drugs
| Structure | Compound | First Approval |
|---|---|---|
|
|
CRINECERFONT
CHEMBL291657
|
2024 |
Source Header